Article
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2013
Floris Giuseppe, Wozniak Agnieszka, Sciot Raf, Li Haifu, Friedman Lori, Van Looy Thomas, Wellens Jasmien, Vermaelen Peter, Deroose Christophe M, Fletcher Jonathan A, Debiec-Rychter Maria, Schöffski Patrick
Abstract excerpt
PURPOSE: Oncogenic signaling in gastrointestinal stromal tumors (GIST) is sustained via PI3K/AKT pathway. We used a panel of six GIST xenograft models to assess efficacy of GDC-0941 as single agent or in combination with imatinib (IMA). EXPERIMENTAL DESIGN: Nude mice (n = 136) were grafted bilaterally with human GIST carrying diverse KIT mutations. Mice were orally dosed over four weeks, grouped as follows: (A)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.